Find the right fit for you - faster
Get tailored insights about working at CatSci in one quick step.
CatSci Snapshot
CatSci is constantly evolving to ensure that the demands of modern drug development can be addressed with state-of-the-art technology and moving forward, aligning itself towards the fourth industrial revolution: CatSci 4.0. We want to be a “Digital First, Intelligent Automation Next company”, freeing up the hands and minds of our talented scientists to solve your drug development challenges. We will exploit the data we produce and combine it with externally sourced knowledge and information – taking full advantage of any new developments in our space and beyond – to optimise the work that we do to efficiently and effectively deliver innovative solutions for our customers.
CatSci Ltd was formed in December 2010, after the founders saw an opportunity in the market for a unique catalyst screening company. CatSci was consequently spun out of AstraZeneca’s Catalyst Screening Facility, replicating the same high laboratory standards and experimental workflows. We soon enhanced our offering to provide end-to-end, perfect-for-purpose process research and development services for emerging, mid-sized and large pharma organisations worldwide.
CatSci has since developed into the fully integrated innovation partner for medicines development that it is today. Our fully integrated chemical development, material science, pre-formulation and analytical development teams leverage their extensive knowledge across the CMC landscape and refined workflows based on world-leading approaches that have evolved over years of experience with large pharma. This allows us to deliver complex projects on time and to the requisite quality. In 2020, we created a network of trusted partners across the pharmaceutical supply chain to add strategic value to our customers’ projects throughout the journey from molecule to medicine. In 2021, we opened our second facility in Dagenham that we envisage becoming a Centre of Excellence for analytical science, including new modalities. In 2022, we received investment from Keensight Capital to support the expansion of our workforce, laboratories and offering so that we can continuously offer more and better to our customers.
CatSci has since developed into the fully integrated innovation partner for medicines development that it is today. Our fully integrated chemical development, material science, pre-formulation and analytical development teams leverage their extensive knowledge across the CMC landscape and refined workflows based on world-leading approaches that have evolved over years of experience with large pharma. This allows us to deliver complex projects on time and to the requisite quality. In 2020, we created a network of trusted partners across the pharmaceutical supply chain to add strategic value to our customers’ projects throughout the journey from molecule to medicine. In 2021, we opened our second facility in Dagenham that we envisage becoming a Centre of Excellence for analytical science, including new modalities. In 2022, we received investment from Keensight Capital to support the expansion of our workforce, laboratories and offering so that we can continuously offer more and better to our customers.
